AllSight
OMDA · SERVICES-HEALTH SERVICES · 8-K · Item 2.02 · Aug 6, 2026

Profitable growth accelerates as full-year EBITDA outlook jumps

Omada Health, Inc. (OMDA) — AllSight decodes this SEC 8-K in plain English, versus what the market expected.

The quarter landed materially better than the prior plan. Revenue reached $87.8 million, up 43% year over year, while adjusted EBITDA reached $10.8 million versus a $0.2 million loss last year; the company also produced its first reported quarterly GAAP operating profit, at $3.5 million. (Income Statement; Adjusted EBITDA reconciliation) No reliable published Q2 consensus was available to substantiate a precise revenue or EPS beat, so the clearest expectation anchor is the company’s prior outlook.

MetricQ2 2026Q2 2025 / Prior outlookRead-through
Revenue$87.8M$61.4M+43% year over year (Income Statement)
GAAP gross margin73%66%7-point improvement (Non-GAAP gross profit reconciliation)
GAAP net income$5.3M$(5.3)MFirst profitable quarter on this comparison (Income Statement)
Adjusted EBITDA$10.8M$(0.2)M$10.9M year-over-year improvement (Adjusted EBITDA reconciliation)
Six-month operating cash flow$(7.8)M$(13.3)MImproved, but still negative (Cash Flow statement)
Full-year adjusted EBITDA outlook$21M-$27MPrior: $14M-$20MRaised at both ends (Financial outlook)

The guidance increase is the strongest signal in the filing. The new $21 million to $27 million adjusted EBITDA range is up from $14 million to $20 million, lifting the midpoint from $17 million to $24 million. That is not merely a confirmation of a strong quarter; it indicates management believes the profitability improvement is carrying into the second half. (Financial outlook)

Operating leverage is becoming visible, but cash conversion has not caught up. Gross margin expanded to 73% from 66%, while sales and marketing fell to 32% of revenue from 35% and general and administrative expense to 15% from 18%. However, six-month free cash flow remained negative at $11.0 million, with accounts receivable rising to $56.6 million from $34.6 million at year-end; the filing also records a $23.2 million working-capital use from accounts receivable. (Non-GAAP gross profit reconciliation; Non-GAAP operating expense reconciliation; Cash Flow statement; Balance Sheet)

The CEO transition looks more like planned succession than a strategic reset. Sean Duffy will become Executive Chairman on January 1, 2027, while President Wei-Li Shao—already responsible for the operating agenda and P&L—becomes CEO. Duffy remains involved in partnerships and strategy, reducing the immediate disruption signal, though investors will still need to assess execution under the new chief executive. (Leadership Transition; Management commentary)

Net read: a genuine positive surprise on the forward earnings profile, tempered by continued cash burn. The filing changes the picture from “growth approaching profitability” to “growth with meaningful reported profitability,” and the raised EBITDA range confirms that improvement is ahead of the prior expectation. Negative free cash flow and a founder-to-executive-chair transition are the main qualifications, but neither offsets the strength of the earnings and guidance update.

Read the original 8-K on SEC EDGAR ↗
Open live on AllSight — the whole market, decoded →
AllSight turns SEC filings into plain-English, neutral reads and objective market context. We explain what happened and how it lands versus expectations — we do not give investment advice or predict prices. Decoded straight from the filing; check it against the source.